| 초록 |
Objectives: The recently proposed metabolic dysfunction-associated fatty liver disease (MAFLD) has been suggested to better reflect risk of developing chronic kidney disease (CKD). This study aimed to evaluate the association between the triglyceride-glucose (TyG) index and CKD progression in patients with MAFLD.
Methods: In the data from the medical records database in Gangnam Severance Hospital from 2006 through 2020, a longitudinal analysis included participants with CKD. MAFLD was diagnosed in patients with was diagnosed in individuals with hepatic steatosis and at least one of the conditions as follows: 1) overweight or obese (defined as body mass index [BMI] ≥ 23 kg/m2), 2) type 2 diabetes mellitus, or 3) two or more metabolic abnormalities. Progression of CKD was defined by a reduction in the GFR ≥30% of baseline. Logistic regression analyses were used to determine the association between TyG index and progression of CKD by adjusting for the influence of confounders.
Results: The study included 4,286 patients, of whom 582 had MAFLD. Mean age was 51.49 ± 11.451 years. After adjusting for age, sex, systolic blood pressure, fasting plasma glucose, CRP, LDL-cholesterol and smoking status, TyG index was associated with progression of CKD [OR 1.760 (1.089-2.844), P=0.021].
Conclusions: Our study showed that TyG index was significantly associated with progression of CKD in patients with MAFLD.
|